STAR-1 topline results expected in March 2025 - - Over 30 million acne patients seek treatment in the U.S. each year - - Phase 2b for DMT310 achieved statistically significant r ...

Independent valuation of PsyLabs values Psyence Biomed’s stake at approximately $2 million, doubling in value. Debt-for-equity swap with Psyence Group and Newcourt SPAC Sponsor ...

据该公司称,FDA的检查产生了某些观察结果,Applied Therapeutics已经做出回应,并认为已解决任何未决问题。公司表示,所提到的给药错误导致少数患者的药物水平略低于目标水平,但在维持剂量阶段之前已得到纠正。Applied Therapeutics坚持认为,所有必要的详细记录都按照FDA规定保存,并已提供给该机构。

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on APLT stock, giving a Buy rating on November 29.Don't Miss our ...

Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Applied Therapeutics regarding the New Drug Application (NDA) for govorestat for the treatment of classic ...

Novartis will partner with PTC Therapeutics to develop PTC’s PTC518 Huntington's disease program and an unspecified number of related molecules, through an up-to-$2.9 billion exclusive global license ...

Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") . Such investors are advised to contact Danielle Peyton at ...

Executives at Applied Therapeutics told analysts they were surprised by the agency’s refusal to approve the company’s ...

The breast cancer drug Enhertu will be added to China’s national health insurance scheme beginning in the new year — despite ...

Former FDA Commissioner Scott Gottlieb, MD, warned " it will cost lives " if Robert F. Kennedy Jr. is allowed to implement ...

Shares of Applied Therapeutics (APLT) plummeted 76.3% after the FDA rejected approval for its drug intended to treat a rare genetic metabolic disorder. Target Corporation’s (TGT) shares jumped 1.7% on ...